Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 9/20 | 0.56 |
| ▸ | CA1 | P00915 | 7/20 | 0.56 |
| ▸ | CA9 | Q16790 | 7/20 | 0.56 |
| ▸ | CA6 | P23280 | 5/20 | 0.56 |
| ▸ | CA7 | P43166 | 5/20 | 0.56 |
| ▸ | CA5A | P35218 | 5/20 | 0.56 |
| ▸ | CA12 | O43570 | 5/20 | 0.56 |
| ▸ | CA4 | P22748 | 4/20 | 0.56 |
| ▸ | CA5B | Q9Y2D0 | 4/20 | 0.56 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.56 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.56 |
| ▸ | PTGES2 | Q9H7Z7 | 6/20 | 0.53 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | HSD11B1 | P28845 | 1/20 | 0.46 |
| ▸ | CA3 | P07451 | 2/20 | 0.45 |
| ▸ | MAOB | P27338 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL121865 | 1.00 | CA2 (0.56) | CA2CA1CA9CA6CA7 | |
| Hydrochloric Acid SCHEMBL27864427 | 0.98 | CA2 (0.54) | CA2CA1CA9CA6CA7 | |
| SCHEMBL2323386 | 0.98 | CA2 (0.54) | CA2CA1CA9CA6CA7 | |
| SCHEMBL2323381 | 0.98 | CA2 (0.54) | CA2CA1CA9CA6CA7 | |
| SCHEMBL29578190 | 0.81 | PTGES2 (0.64) | CA2CA1CA9CA6CA7 | |
| SCHEMBL742940 | 0.81 | PTGES2 (0.64) | CA2CA1CA9CA6CA7 | |
| SCHEMBL11647231 | 0.81 | CA1 (0.52) | CA2CA1CA9CA6CA7 | |
| SCHEMBL202947 | 0.81 | CA2 (0.70) | CA2CA1CA9CA6CA7 | |
| SCHEMBL28407818 | 0.81 | CA2 (0.47) | CA2CA1CA9CA6CA7 | |
| SCHEMBL30697126 | 0.79 | HSD11B1 (0.59) | GAATSHRHSD17B10LMNAHSD11B1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2026-03-19 | — | — | US | disclosed |
| EP-4661966-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | Type6 Therapeutics, Inc. (US) | 2025-12-17 | — | — | EP | disclosed |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2025-11-25 | — | — | US | disclosed |
| EP-3707126-B1 | IRE1 SMALL MOLECULE INHIBITORS | UNIV CORNELL (US) | 2025-05-14 | — | — | EP | disclosed |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2024-12-26 | — | — | US | disclosed |
| EP-4469442-A1 | 1,2,3-TRIAZOLE CARBONYL SULFONYLAMIDE COMPOUNDS AND USE THEREOF | PI Industries Ltd. (IN) | 2024-12-04 | — | — | EP | disclosed |
| US-20240300892-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2024-09-12 | — | — | US | disclosed |
| US-12071424-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2024-08-27 | — | — | US | disclosed |
| WO-2024167848-A1 | COMPOUNDS, COMPOSITIONS, AND METHODS OF USE THEREOF | TYPE6 THERAPEUTICS, INC. (US) | 2024-08-15 | — | — | WO | disclosed |
| US-11945784-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2024-04-02 | — | — | US | disclosed |
| CN-116981663-A | Modulators of FPR1 and methods of use thereof | 百放开曼有限公司 | 2023-10-31 | — | — | CN | disclosed |
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2023-08-31 | — | — | US | disclosed |
| WO-2023144711-A1 | 1,2,3-TRIAZOLE CARBONYL SULFONYLAMIDE COMPOUNDS AND USE THEREOF | PI INDUSTRIES LTD. (IN) | 2023-08-03 | — | — | WO | disclosed |
| US-11634403-B2 | IRE1 small molecule inhibitors | CORNELL UNIVERSITY (US) | 2023-04-25 | — | — | US | disclosed |
| CN-112694473-B | 7, 9-disubstituted berberine structural analogue and preparation method and application thereof | 南京林业大学 | 2022-09-20 | — | — | CN | disclosed |
| US-20220251065-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2022-08-11 | — | — | US | disclosed |
| US-20220227730-A1 | TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2022-07-21 | — | — | US | disclosed |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | AMGEN INC (US) | 2022-06-02 | — | — | US | disclosed |
| US-20220024878-A1 | IRE1 SMALL MOLECULE INHIBITORS | CORNELL UNIVERSITY | 2022-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230271935-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | CA2 4217/4885CA1 4652/4885CA9 4397/4885 |
| US-20240300892-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | CA2 3641/4885CA1 3382/4885CA9 3326/4885 |
| US-20240425477-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | CA2 4217/4885CA1 4652/4885CA9 4397/4885 |
| US-20260078091-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | TP53, HIF1AN, MDM2 | CA2 535/4885CA1 1069/4885CA9 1154/4885 |
| US-11634403-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | CA2 4217/4885CA1 4652/4885CA9 4397/4885 |
| US-20220169611-A1 | Piperidinone Derivatives as MDM2 Inhibitors for the Treatment of Cancer | MDM2, TP53, CDKN1A | CA2 3641/4885CA1 3382/4885CA9 3326/4885 |
| US-20220227730-A1 | TREATMENT OF FIBROSIS WITH IRE1 SMALL MOLECULE INHIBITORS | XBP1, DDIT3, ATF4 | CA2 4160/4885CA1 4828/4885CA9 4598/4885 |
| US-11945784-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | CA2 4217/4885CA1 4652/4885CA9 4397/4885 |
| US-12071424-B2 | IRE1 small molecule inhibitors | XBP1, ERN2, ERN1 | CA2 4217/4885CA1 4652/4885CA9 4397/4885 |
| US-20220251065-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | CA2 4217/4885CA1 4652/4885CA9 4397/4885 |
| US-12479818-B2 | Treatment of fibrosis with IRE1 small molecule inhibitors | XBP1, DDIT3, HSP90B1 | CA2 4134/4885CA1 4827/4885CA9 4583/4885 |
| US-20220024878-A1 | IRE1 SMALL MOLECULE INHIBITORS | XBP1, ERN2, ERN1 | CA2 4217/4885CA1 4652/4885CA9 4397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.